Makrina Karaglani

Dr. Makrina Karaglani

Democritus University of Thrace, Faculty of Medicine
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
Maria PanagopoulouMaria Panagopoulou
Maria Panagopoulou
Makrina KaraglaniMakrina Karaglani
Makrina Karaglani
IBIoanna Balgkouranidou
Ioanna Balgkouranidou
EBEirini Biziota
Eirini Biziota
TKTriantafillia Koukaki
Triantafillia Koukaki
Ekaterini ChatzakiEkaterini Chatzaki
Ekaterini Chatzaki

18 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Makrina KaraglaniMakrina Karaglani
Makrina Karaglani
Krystallia GourliaKrystallia Gourlia
Krystallia Gourlia
ITIoannis Tsamardinos
Ioannis Tsamardinos
Ekaterini ChatzakiEkaterini Chatzaki
Ekaterini Chatzaki
Alzheimer’s disease (AD) is the most common form of neurodegenerative dementia and its timely diagnosis remains a major challenge in biomarker discovery. In the present study, we analyzed publicly available high-throughput low-sample -omics datasets from studies in AD blood, by the AutoML technology Just Add Data Bio (JADBIO), to construct accurate predictive models for use as diagnostic biosignatures. Considering data from AD patients and age–sex matched cognitively healthy individuals, we produced three best performing diagnostic biosignatures specific for the presence of AD: A. A 506-feature transcriptomic dataset from 48 AD and 22 controls led to a miRNA-based biosignature via Support Vector Machines with three miRNA predictors (AUC 0.975 (0.906, 1.000)), B. A 38,327-feature transcriptomic dataset from 134 AD and 100 controls led to six mRNA-based statistically equivalent signatures via Classification Random Forests with 25 mRNA predictors (AUC 0.846 (0.778, 0.905)) and C. A 9483-feature proteomic dataset from 25 AD and 37 controls led to a protein-based biosignature via Ridge Logistic Regression with seven protein predictors (AUC 0.921 (0.849, 0.972)). These performance metrics were also validated through the JADBIO pipeline confirming stability. In conclusion, using the automated machine learning tool JADBIO, we produced accurate predictive biosignatures extrapolating available low sample -omics data. These results offer options for minimally invasive blood-based diagnostic tests for AD, awaiting clinical validation based on respective laboratory assays. They also highlight the value of AutoML in biomarker discovery.

2 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Maria PanagopoulouMaria Panagopoulou
Maria Panagopoulou
Makrina KaraglaniMakrina Karaglani
Makrina Karaglani
Vangelis ManolopoulosVangelis Manolopoulos
Vangelis Manolopoulos
IIIoannis Iliopoulos
Ioannis Iliopoulos
ITIoannis Tsamardinos
Ioannis Tsamardinos
Ekaterini ChatzakiEkaterini Chatzaki
Ekaterini Chatzaki
DNA methylation plays an important role in breast cancer (BrCa) pathogenesis and could contribute to driving its personalized management. We performed a complete bioinformatic analysis in BrCa whole methylome datasets, analyzed using the Illumina methylation 450 bead-chip array. Differential methylation analysis vs. clinical end-points resulted in 11,176 to 27,786 differentially methylated genes (DMGs). Innovative automated machine learning (AutoML) was employed to construct signatures with translational value. Three highly performing and low-feature-number signatures were built: (1) A 5-gene signature discriminating BrCa patients from healthy individuals (area under the curve (AUC): 0.994 (0.982–1.000)). (2) A 3-gene signature identifying BrCa metastatic disease (AUC: 0.986 (0.921–1.000)). (3) Six equivalent 5-gene signatures diagnosing early disease (AUC: 0.973 (0.920–1.000)). Validation in independent patient groups verified performance. Bioinformatic tools for functional analysis and protein interaction prediction were also employed. All protein encoding features included in the signatures were associated with BrCa-related pathways. Functional analysis of DMGs highlighted the regulation of transcription as the main biological process, the nucleus as the main cellular component and transcription factor activity and sequence-specific DNA binding as the main molecular functions. Overall, three high-performance diagnostic/prognostic signatures were built and are readily available for improving BrCa precision management upon prospective clinical validation. Revisiting archived methylomes through novel bioinformatic approaches revealed significant clarifying knowledge for the contribution of gene methylation events in breast carcinogenesis.

7 January 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
Maria PanagopoulouMaria Panagopoulou
Maria Panagopoulou
Makrina KaraglaniMakrina Karaglani
Makrina Karaglani
IBIoanna Balgkouranidou
Ioanna Balgkouranidou
CPChrisoula Pantazi
Chrisoula Pantazi
GKGeorge Kolios
George Kolios
Ekaterini ChatzakiEkaterini Chatzaki
Ekaterini Chatzaki

1 October 2015 in Cancer Epidemiology
Verified
Journal Article
Closed access
CNChristos Nikolaidis
Christos Nikolaidis
ENEvangelia Nena
Evangelia Nena
Maria PanagopoulouMaria Panagopoulou
Maria Panagopoulou
IBIoanna Balgkouranidou
Ioanna Balgkouranidou
Makrina KaraglaniMakrina Karaglani
Makrina Karaglani
TCTheodoros C. Constantinidis
Theodoros C. Constantinidis

30 July 2024 in Cells
Verified
Journal Article
Open access
PDF file
AKAthina Kyriazi
Athina Kyriazi
Makrina KaraglaniMakrina Karaglani
Makrina Karaglani
Sofia AgelakiSofia Agelaki
Sofia Agelaki
SBStavroula Baritaki
Stavroula Baritaki
The role of the microbiome in cancer and its crosstalk with the tumor microenvironment (TME) has been extensively studied and characterized. An emerging field in the cancer microbiome research is the concept of the intratumoral microbiome, which refers to the microbiome residing within the tumor. This microbiome primarily originates from the local microbiome of the tumor-bearing tissue or from translocating microbiome from distant sites, such as the gut. Despite the increasing number of studies on intratumoral microbiome, it remains unclear whether it is a driver or a bystander of oncogenesis and tumor progression. This review aims to elucidate the intricate role of the intratumoral microbiome in tumor development by exploring its effects on reshaping the multileveled ecosystem in which tumors thrive, the TME. To dissect the complexity and the multitude of layers within the TME, we distinguish six specialized tumor microenvironments, namely, the immune, metabolic, hypoxic, acidic, mechanical and innervated microenvironments. Accordingly, we attempt to decipher the effects of the intratumoral microbiome on each specialized microenvironment and ultimately decode its tumor-promoting or tumor-suppressive impact. Additionally, we portray the intratumoral microbiome as an orchestrator in the tumor milieu, fine-tuning the responses in distinct, specialized microenvironments and remodeling the TME in a multileveled and multifaceted manner.